Genvax Technologies

Develops mRNA nanoparticle vaccines for animals

Genvax Technologies

Develops mRNA nanoparticle vaccines for animals

Overview

Genvax Technologies develops mRNA nanoparticle vaccines for animals to prevent and treat veterinary diseases, serving livestock producers, clinics, and animal health organizations. Its vaccines use an mRNA platform packaged in nanoparticles to trigger an immune response, with products advanced through R&D and then sold commercially. The company differentiates itself with a founder-led team tied to a proven track record in animal vaccines and a rapid-response approach to new animal health challenges. Its goal is to improve global animal health by quickly bringing effective animal vaccines to market.

Work here?Claim your company

About Genvax Technologies

Simplify's Rating

Why Genvax Technologies is rated

B-

Rated B on Competitive Edge

Rated B on Growth Potential

Rated C on Differentiation

Industries

BiotechnologyHealthcare

Company Size

1-10

Company Stage

Early VC

Total Funding

$10.1M

Headquarters

Ames, IA

Founded

2021

Get referred to Genvax Technologies

See people who can refer or advise you

Simplify's take

What believers are saying

FFAR and Genvax funded a June 2025 H5N1 dairy-cow vaccine program.
The February 2025 Seed Plus round added United Animal Health and strategic ag investors.
A 2026 company presentation targets first swine vaccine approval in H1 2027.

What critics are saying

H1 2027 approval expectations remain unproven; no commercial vaccine sold today.
USDA CVB and diagnostic validation failures would stall swine and H5N1 programs.
Merck, Zoetis, and Elanco can outspend Genvax if efficacy slips.

What makes Genvax Technologies unique

Joel Harris and Hank Harris sold Harrisvaccines to Merck in 2015.
Genvax pairs saRNA vaccines with nanoparticles for herd-specific livestock outbreak response.
Ames, Iowa operations target USDA veterinary biologics pathways before commercial animal-health launches.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$10.1M

Above

Industry Average

Funded Over

3 Rounds

Early VC funding comparison data is currently unavailable. We're working to provide this information soon!

Early VC Funding Comparison Coming Soon

Benefits

Health Insurance
Company Equity
Paid Vacation

Company News

Feedstuffs

Apr 25th, 2025

FFAR research grant targets H5N1 vaccine for dairy cows

Together, the Foundation for Food & Agriculture Research (FFAR) and Genvax Technologies are investing $278,163 into a Rapid Outcomes from Agricultural Research (ROAR) grant to develop an H5N1 vaccine for dairy cows.

VCNewsDaily

Feb 5th, 2025

Genvax Technologies Closes Seed Plus Round

Genvax Technologies, a startup focused on RNA vaccine production for animal health, has closed its Series Seed Plus funding round. This funding will help the company move towards USDA approval of its vaccines, enhancing response to animal disease outbreaks and improving livestock health. The round was led by United Animal Health, with participation from Johnsonville Ventures, Iowa Farm Bureau's Rural Vitality Funds, Iowa Corn Growers Association, and Ag Startup Engine.

PR Newswire

Feb 4th, 2025

Genvax Technologies Secures Seed Plus Funding

Genvax Technologies closed a Series Seed Plus round and appointed Dr. Lucas Huntimer as Chief Scientific Officer. The company, founded in February 2021, focuses on RNA vaccines for animal health. Their platform allows rapid development of vaccines for diseases like HPAI and ASF. United Animal Health led the financing, supported by Johnsonville Ventures and others. In August 2022, Genvax raised $6.5 million in a Seed round.

Intelligence360 News

Jul 3rd, 2024

Genvax Technologies Has Filed A Notice Of An Exempt Offering Of Securities To Raise $5,249,991.00 In New Equity Investment.

Genvax Technologies has filed a notice of an exempt offering of securities to raise $5,249,991.00 in New Equity Investment. Genvax Technologies has filed a notice of an exempt offering of securities to raise $5,249,991.00 in New Equity Investment.According to filings with the U.S. Securities and Exchange Commission, Genvax Technologies is raising up to $5,249,991.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Joel Harris played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.About Genvax TechnologiesGenvax is a startup animal vaccine company located in Ames, Iowa. We have a dynamic team of experienced scientists and entrepreneurs poised to develop next generation RNA + nanoparticle vaccines for animal health. This isnt the first go-around for co-founders Joel Harris and Dr

U.S. Securities and Exchange Commission

Jun 26th, 2024

SEC FORM D

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.The reader should not assume that the information is accurate and complete.

Recently Posted Jobs